Haiying Liu

机构：NILU · ORCID：0000-0001-6852-8256

发表论文 43 篇 · 总被引 1144 次 · h-index 13

代表论文

• Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial (2020 · The Lancet Oncology · 被引 383)
• From autophagy to mitophagy: the roles of P62 in neurodegenerative diseases (2017 · Journal of Bioenergetics and Biomembranes · 被引 129)
• Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study (2021 · Journal of Clinical Oncology · 被引 66)
• Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). (2020 · Journal of Clinical Oncology · 被引 28)
• Analysis of the Clinical Predictive Value of the Novel Inflammatory Indices SII, SIRI, MHR and NHR in Patients with Acute Myocardial Infarction and Their Extent of Coronary Artery Disease (2024 · Journal of Inflammation Research · 被引 27)
• The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys (2016 · PLoS ONE · 被引 24)